Bortezomib is often a proteasome inhibitor utilized to treat many myeloma in individuals which have not been productively taken care of with a minimum of two former therapies.
To scale back the chance of dizziness and lightheadedness, rise up slowly but surely when rising from a sitting down or lying posture.
Most sufferers do create hypoglycemia, so lowering the dose from the oral hypoglycemic agent may be vital.
Observe Intently (1)triclabendazole will increase the degree or result of bortezomib by impacting hepatic enzyme CYP2C19 metabolism.
This compound belongs to The category of natural compounds called phenylalanine and derivatives. These are generally compounds containing phenylalanine or simply a by-product thereof resulting from reaction of phenylalanine with the amino team or maybe the carboxy team, or through the replacement of any hydrogen of glycine by a heteroatom.
Keep an eye on Intently (1)belzutifan will reduce the level or outcome of bortezomib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
bortezomib boosts Ritobegron HCl amounts of lomitapide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. Lomitapide dose mustn't exceed thirty mg/working day.
bortezomib will enhance the degree or outcome of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Carefully. Lessen nightly dose of lemborexant advisable if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification.
Remember to see your overall health care professional For more info regarding your unique professional medical ailment and the usage of this drug.
erythromycin lactobionate will raise the level or effect of bortezomib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
Monitor Carefully (one)lenacapavir will raise the level or outcome of bortezomib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
apalutamide will lower the level or outcome of bortezomib by influencing hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a solid CYP2C19 inducer, with medicine that happen to be CYP2C19 substrates may lead to reduced exposure to those remedies.
cenobamate 2' will enhance the degree or outcome of bortezomib by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Observe Closely. Take into consideration a dose reduction of CYP2C19 substrates, as clinically Urolithin A suitable, when made use of concomitantly with cenobamate.
bortezomib will boost the amount or result of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or moderate CYP2C19 inhibitors may well enhance mavacamten systemic publicity, leading to coronary heart failure resulting from systolic dysfunction.